Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative Registry.
OBJECTIVE
We sought to clarify risk factor profiles and current treatment of Japanese patients with stroke, myocardial infarction (MI), and nonvalvular atrial fibrillation (NVAF) using the database of the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE).


METHODS
J-TRACE is a nationwide multicenter cooperative cohort of Japanese patients with MI, stroke, and NVAF. Baseline characteristics of 8087 Japanese patients (5804 male, average age 68.7 years) with history of stroke (n=3554), MI (n=2291), or NVAF (n=2242) were analyzed.


RESULTS
History of stroke (14.7%) was more frequent than history of MI (2.6%) in patients with stroke, whereas history of stroke (6.6%) was less frequent than history of MI (7.6%) in patients with MI. In patients with NVAF, history of stroke (14.3%) was far more frequent than history of MI (3.4%). Hypertension was more frequent in stroke (74.4%) than MI (62.0%) or NVAF (57.7%), whereas hypercholesterolemia, diabetes mellitus, and cigarette smoking were more prevalent in patients with MI (56.1%, 35.1%, and 33.3%, respectively) than in those with stroke (35.7%, 22.4%, and 19.7%, respectively) or NVAF (26.9%, 17.2%, and 16.1%, respectively). Alcohol consumption (34.9%) and obesity (body mass index>25) (32.8%) were most common in patients with NVAF. In all patients, nonmedication rates were higher in patients with hypercholesterolemia (29.8%) or diabetes (36.9%) than in those with hypertension (9.5%). Warfarin was used in 58.9% of patients with low-risk and 75.4% with high-risk NVAF.


CONCLUSIONS
Risk factor profiles and their modification were not similar among patients in Japan with MI, stroke, and NVAF, although they share a high risk of thrombotic events.
Uchiyama
Shinichiro
S
Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan. Electronic address: suchiyam@nij.twmu.ac.jp.
Shibata
Yoshisato
Y
Department of Cardiology, Miyazaki Medical Association Hospital, Miyazaki, Japan.
Hirabayashi
Takayuki
T
Department of Cardiology, Sunagawa City Medical Center, Sunagawa, Japan.
Mihara
Ban
B
Department of Neurology, Institute of Brain and Vessel, Mihara Memorial Hospital, Isezaki, Japan.
Hamashige
Naohisa
N
Department of Cardiology, Chikamori Hospital, Kochi, Japan.
Kitagawa
Kazuo
K
Department of Neurology, Osaka University School of Medicine, Osaka, Japan.
Goto
Shinya
S
Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Origasa
Hideki
H
Department of Biostatistics, Toyama University Graduate School, Toyama, Japan.
Shimada
Kazuyuki
K
Department of Internal Medicine, Jichi Medical School, Shimono, Japan.
Kobayashi
Hiroyuki
H
Department of Clinical Pharmacology, Tokai University School of Medicine, Isehara, Japan.
Isozaki
Mitsuhiro
M
Department of Clinical Pharmacology, Tokai University School of Medicine, Isehara, Japan.
Ikeda
Yasuo
Y
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
D000368:Aged; D001281:Atrial Fibrillation / Q000453:epidemiology*; D002311:Cardiomyopathy, Dilated / Q000150:complications / Q000453:epidemiology; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000453:epidemiology; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000453:epidemiology*; D012042:Registries; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy / Q000453:epidemiology*; D013927:Thrombosis / Q000150:complications
D005343:Fibrinolytic Agents